 SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 PRNewswire -- Sutro Biopharma, Inc. NASDAQ: STRO, a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that the U.S. Food and Drug Administration FDA has granted Fast Track designation for STRO-002, a folate receptor alpha FolRα-targeting antibody-drug conjugate ADC, for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of systemic therapy. 